Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis

PLoS One. 2012;7(5):e36676. doi: 10.1371/journal.pone.0036676. Epub 2012 May 4.

Abstract

Background: Liver stiffness measurement (LSM) using transient elastography (FibroScan®) can assess liver fibrosis noninvasively. This study investigated whether LSM can predict the development of liver-related events (LREs) in chronic hepatitis B (CHB) patients showing histologically advanced liver fibrosis.

Methods: Between March 2006 and April 2010, 128 CHB patients with who underwent LSM and liver biopsy (LB) before starting nucleot(s)ide analogues and showed histologically advanced fibrosis (≥F3) with a high viral loads [HBV DNA ≥2,000 IU/mL] were enrolled. All patients were followed regularly to detect LRE development, including hepatic decompensation (variceal bleeding, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome) and hepatocellular carcinoma (HCC).

Results: The mean age of the patient (72 men, 56 women) was 52.2 years. During the median follow-up period [median 27.8 (12.6-61.6) months], LREs developed in 19 (14.8%) patients (five with hepatic decompensation, 13 with HCC, one with both). Together with age, multivariate analysis identified LSM as an independent predictor of LRE development [P<0.044; hazard ratio (HR), 1.038; 95% confidence interval (CI), 1.002-1.081]. When the study population was stratified into two groups using the optimal cutoff value (19 kPa), which maximized the sum of sensitivity (61.1%) and specificity (86.2%) from a time-dependent receiver operating characteristic curve, patients with LSM>19 kPa were at significantly greater risk than those with LSM≤19 kPa for LRE development (HR, 7.176; 95% CI, 2.257-22.812; P = 0.001).

Conclusion: LSM can be a useful predictor of LRE development in CHB patients showing histologically advanced liver fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Elasticity Imaging Techniques*
  • Female
  • Hepatitis B, Chronic / complications*
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Liver / diagnostic imaging*
  • Liver / drug effects
  • Liver / pathology
  • Liver / virology
  • Liver Cirrhosis / complications*
  • Liver Cirrhosis / diagnostic imaging
  • Liver Cirrhosis / pathology*
  • Male
  • Middle Aged
  • Risk Assessment
  • Risk Factors
  • Viral Load

Substances

  • Antiviral Agents